The Germline <i>HSD3B1</i> Variant Is Associated With Response to Androgen Deprivation Therapy and Abiraterone but not With Response to Enzalutamide in Chinese Prostate Cancer Patients
The HSD3B1 germline variant (1245C) is linked to earlier ADT failure and diminished efficacy of abiraterone but does not affect enzalutamide in the treatment of PCa patients. These findings underscore its potential as a biomarker to guide personalized treatment in PCa.
Authors
- T.Y. Kam (ORCID: https://orcid.org/0000-0002-4247-7072)
- A. Lam (ORCID: https://orcid.org/0000-0001-5731-7146)
- Qijun Du (ORCID: https://orcid.org/0000-0002-4299-1178)
- Rong Na (ORCID: https://orcid.org/0000-0001-7470-5108)
- Xiaohao Ruan (ORCID: https://orcid.org/0000-0001-8373-5237)
- Chi Yao (ORCID: https://orcid.org/0000-0002-6958-6535)
- Tsun Tsun Stacia Chun (ORCID: https://orcid.org/0009-0009-6715-7815)
- Yongqiu Wu (ORCID: https://orcid.org/0000-0003-4851-6383)
- Ruofan Shi (ORCID: https://orcid.org/0009-0005-1001-390X)
- Dan-feng Xu
- Da Huang (ORCID: https://orcid.org/0000-0001-9021-7438)
- Kuen Chan
- Sk Subidh Ali (ORCID: https://orcid.org/0009-0008-6990-3546)
Institutions
- Shanghai Jiao Tong University (CN)
- Ruijin Hospital (CN)
- Pamela Youde Nethersole Eastern Hospital (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- The Prostate
- Published
- 2025-11-04
- DOI
- https://doi.org/10.1002/pros.70089
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China